Medtronic (MDT)

Its cardiovascular franchise includes pacemakers, implantable defibrillators, cardiac resynchronisation devices, transcatheter heart valves, stents, ablation systems, and related monitoring technologies. These products place Medtronic at the centre of major treatment areas such as heart rhythm disorders, structural heart disease, coronary and peripheral vascular disease, and cardiac surgery.

The company also has large positions in surgical tools, advanced energy systems, stapling, patient monitoring, respiratory care, spinal implants, neuromodulation, and neurovascular products. In diabetes, Medtronic is known for insulin pump and continuous glucose monitoring technologies designed to help patients manage blood glucose more effectively.

Medtronic sells primarily to healthcare institutions and physicians, with the United States, Western Europe, Japan, and other developed markets representing important sources of demand. International revenue is a major part of the business, reflecting the global need for devices that improve outcomes, shorten hospital stays, or support minimally invasive care.

As an investment, Medtronic is typically viewed as a diversified healthcare equipment company rather than a single-product medical device maker. Its scale, regulatory expertise, physician relationships, and large installed base provide competitive advantages, while growth depends on innovation, procedure volumes, reimbursement trends, and the company’s ability to bring clinically useful technologies to market.